Acetaminophen
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Mild to moderate pain | Adults and children ≥2 years (oral/rectal); adults and children ≥2 years (IV, with specific weight-based criteria) | Monotherapy or combination | FDA Approved |
| Fever reduction | Adults and children (including neonates ≥28 weeks gestational age for IV) | Monotherapy | FDA Approved |
Acetaminophen is the most widely used analgesic and antipyretic worldwide. First approved in the United States in 1951, it remains the first-line choice for mild to moderate pain and fever in patients who cannot take NSAIDs, including those with peptic ulcer disease, renal impairment, asthma-aspirin sensitivity, or anticoagulant therapy. It is also the preferred analgesic/antipyretic during pregnancy. While effective for pain and fever, acetaminophen has no clinically significant anti-inflammatory activity at standard doses.
Acetaminophen is a frequent component of combination prescription products with opioids (codeine, hydrocodone, oxycodone, tramadol). The FDA has mandated that all prescription combination products limit acetaminophen to 325 mg per dosage unit to reduce inadvertent hepatotoxicity from multiple-source acetaminophen exposure. Evidence quality: FDA regulatory action (2011).
Dosing
Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Adult pain/fever — oral (regular-strength) | 650 mg q4–6h | 650 mg q4–6h | 3,250 mg/day (OTC labelling) | OTC labelling now recommends max 3,250 mg/day for general consumers. Healthcare professionals may use up to 4,000 mg/day in selected patients under supervision. Total daily dose includes ALL sources of acetaminophen |
| Adult pain/fever — oral (extra-strength) | 1,000 mg q6h | 1,000 mg q6h | 3,000–4,000 mg/day | Max 3,000 mg/day for chronic use or patients with hepatic risk factors; up to 4,000 mg/day short-term under medical guidance. |
| Adult pain/fever — IV (≥50 kg) | 1,000 mg q6h or 650 mg q4h | Same | 4,000 mg/day | Infuse over 15 minutes. Ensure total from all routes does not exceed max. FDA IV PI |
| Adult pain/fever — IV (<50 kg) | 15 mg/kg q6h or 12.5 mg/kg q4h | Same | 75 mg/kg/day (not to exceed 3,750 mg) | Weight-based dosing critical to avoid hepatotoxicity in underweight adults. FDA IV PI |
| Paediatric pain/fever — oral (≥2 years) | 10–15 mg/kg q4–6h | 10–15 mg/kg q4–6h | 75 mg/kg/day (not to exceed 4,000 mg) | Use weight-based dosing, not age-based. Minimum interval 4 hours, max 5 doses/24h. |
| Elderly or hepatic risk factors | 325–500 mg q6h | 325–500 mg q6h | 2,000 mg/day | Reduce max dose in chronic alcohol users (≥3 drinks/day), malnourished patients, or those with chronic liver disease. Some guidelines suggest ≤2 g/day in these populations. |
Acetaminophen is an ingredient in over 600 OTC and prescription products. Patients frequently exceed the maximum daily dose unknowingly by combining multiple acetaminophen-containing preparations (e.g., taking Tylenol for pain and NyQuil for cold symptoms simultaneously). Accidental overdose from multi-product use is the leading cause of acetaminophen-related acute liver failure in the United States (~500 deaths and 50,000 emergency department visits annually). Always ask patients to list ALL medications they are taking and check for acetaminophen content.
Pharmacology
Mechanism of Action
The precise mechanism of acetaminophen remains incompletely understood despite decades of use. Current evidence indicates that its analgesic and antipyretic effects are primarily centrally mediated. Acetaminophen inhibits cyclooxygenase (COX) activity in the central nervous system, reducing prostaglandin E2 synthesis in the hypothalamus (antipyresis) and modulating descending serotonergic pain pathways. Unlike NSAIDs, acetaminophen has negligible inhibition of peripheral COX-1 and COX-2 at therapeutic doses, which explains its lack of anti-inflammatory activity and its favourable gastrointestinal and platelet safety profile. Additional proposed mechanisms include interaction with the endocannabinoid system via its metabolite AM404 and modulation of TRP channel receptors (including TRPA1).
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapid oral absorption; bioavailability ~88%; Tmax 10–60 min (IR), 60–120 min (ER); rectal absorption variable and slower; IV Cmax up to 70% higher than equivalent oral dose | IV provides faster and more predictable peak levels; rectal route unreliable for acute pain; food may delay but does not reduce oral absorption significantly |
| Distribution | Vd ~0.9 L/kg; protein binding 10–25%; widely distributed to most body tissues except fat; crosses placenta and blood-brain barrier | Low protein binding means minimal displacement interactions; placental transfer explains the need for caution in pregnancy despite general safety |
| Metabolism | Hepatic first-order kinetics via 3 pathways: glucuronidation (40–67%, via UGT1A1/1A6/1A9), sulfation (20–40%, via SULT1A1), and CYP2E1 oxidation to toxic NAPQI (~5–15%); NAPQI is normally detoxified by glutathione conjugation | NAPQI is the critical toxic metabolite. At supratherapeutic doses or with glutathione depletion (fasting, alcoholism, malnutrition), NAPQI accumulates and causes centrilobular hepatic necrosis. CYP2E1 induction (chronic alcohol, isoniazid) increases NAPQI production |
| Elimination | t½ 1.25–3 h (adults, oral); 2.4 h (adults, IV); prolonged in hepatic impairment and neonates (~7 h); >90% excreted renally as metabolites within 24 h; <5% as unchanged drug | Short half-life supports q4–6h dosing; prolonged half-life after overdose (>4 h on Rumack-Matthew nomogram) predicts hepatotoxicity |
Side Effects
At recommended doses, acetaminophen has an exceptionally favourable safety profile compared to NSAIDs and opioids. Most adverse effects occur with supratherapeutic dosing or in patients with hepatic risk factors. Incidence data below are from the IV formulation placebo-controlled clinical trials (FDA PI Table 4, N=402 acetaminophen vs N=379 placebo). Important context: These trials were conducted in perioperative settings where background rates of nausea, vomiting, and headache are inherently high. The absolute incidence rates appear elevated, but the drug-attributable excess over placebo is small (typically 1–4%). With oral acetaminophen at recommended doses, the side-effect profile is essentially indistinguishable from placebo in most clinical settings.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 34% (vs 31% placebo) | High absolute rate reflects perioperative setting; drug-attributable excess is ~3%. With oral use at therapeutic doses, nausea incidence is comparable to placebo (FDA PI Table 4) |
| Vomiting | 15% (vs 11% placebo) | Same perioperative context; ~4% excess over placebo. Rarely attributable to oral acetaminophen (FDA PI Table 4) |
| Headache | 10% (vs 9% placebo) | Only ~1% excess over placebo; consider medication overuse headache with chronic oral use (FDA PI Table 4) |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Insomnia | 7% (vs 5% placebo) | Reported in perioperative IV trials; ~2% excess over placebo; infrequent with oral formulations (FDA PI Table 4) |
| Constipation | ≥1% (IV, all trials) | Reported at ≥1% and greater frequency than placebo in pooled IV clinical trial data (FDA PI) |
| Transaminase elevation | 1–3% | Mild, typically transient elevations at doses near 4 g/day for >4 days; usually self-limiting; monitor if prolonged use at max dose |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Acute hepatotoxicity / hepatic failure | Leading cause of acute liver failure in the US; ~500 deaths/year | 24–72 h after toxic dose; peak transaminase elevation at 72–96 h | N-acetylcysteine (NAC) is the specific antidote, most effective if given within 8 hours. Use Rumack-Matthew nomogram to assess risk. Contact Poison Control: 1-800-222-1222 (FDA PI) |
| Serious skin reactions (SJS, TEN, AGEP) | Very rare (FDA safety communication 2013) | Days to weeks | Discontinue immediately; dermatology consultation; do not rechallenge. FDA issued a safety communication in August 2013 (FDA Safety Communication) |
| Anaphylaxis / hypersensitivity | Very rare | Minutes to hours | Discontinue and manage per anaphylaxis protocols; contraindicated for future use (FDA PI) |
| Acute kidney injury (in overdose) | Uncommon; usually accompanies severe hepatotoxicity | 48–96 h after toxic ingestion | Supportive management; NAPQI also causes direct renal tubular injury at toxic doses |
Acetaminophen is the most common cause of acute liver failure in the United States, accounting for approximately 46% of all cases. Hepatic injury results from the accumulation of the toxic metabolite NAPQI when glutathione stores are depleted. The toxic threshold for a single acute ingestion is generally ≥150 mg/kg in adults (some sources cite an absolute threshold of 7.5–12 g depending on body weight and risk factors). Risk factors that lower this threshold include chronic alcohol use (≥3 drinks/day), fasting or malnutrition, concomitant CYP2E1 inducers (isoniazid, phenobarbital), and pre-existing liver disease. N-acetylcysteine (NAC) is the specific antidote and is extremely effective when administered within 8 hours of ingestion.
Drug Interactions
Acetaminophen is metabolised primarily by phase II conjugation (glucuronidation, sulfation) with minor CYP2E1-mediated oxidation. Its low protein binding and non-CYP-dependent primary pathways give it a relatively benign interaction profile, but clinically important interactions exist with warfarin, alcohol, and CYP2E1 inducers.
Monitoring
- Hepatic function (LFTs)Baseline and periodically for chronic use at max doses
Trigger-basedNot required for short-term OTC use at recommended doses. Monitor ALT/AST if using ≥3 g/day chronically, in patients with hepatic risk factors (chronic alcohol, malnutrition, pre-existing liver disease), or if clinical signs of hepatotoxicity develop. - Total daily acetaminophen intakeAt each encounter
RoutineCritically important: reconcile ALL sources of acetaminophen including OTC cold/flu preparations, prescription opioid combinations, and sleep aids. This is the single most important safety intervention. - Serum acetaminophen level (overdose)4 hours post-ingestion
Trigger-basedPlot on Rumack-Matthew nomogram to determine NAC treatment need. Levels drawn before 4 hours cannot be interpreted reliably. In extended-release formulations, consider repeat levels at 4–8 hours. - INR (warfarin patients)Within 1 week of starting regular acetaminophen
Trigger-basedINR may increase with acetaminophen doses >2 g/day for >1 week. More frequent monitoring recommended when starting, changing dose, or stopping acetaminophen in warfarin patients. - Pain/fever responseAt each encounter
RoutineAssess efficacy and need for continued therapy. If inadequate pain control at max recommended doses, consider multimodal approach rather than exceeding dose limits.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to acetaminophen: Rare but documented, including anaphylaxis. Do not rechallenge (FDA PI).
- Severe hepatic impairment or severe active hepatic disease: Listed as a contraindication for prescription acetaminophen products (FDA IV PI).
Relative Contraindications (Specialist Input Recommended)
- Chronic liver disease (Child-Pugh A or B): Use with caution at reduced doses (≤2 g/day). The combination of reduced glutathione stores, impaired glucuronidation capacity, and altered CYP activity increases hepatotoxicity risk.
- Chronic alcohol use disorder (≥3 drinks/day): CYP2E1 induction plus glutathione depletion creates a high-risk profile for NAPQI accumulation. Limit to ≤2 g/day.
- Malnutrition, fasting, or eating disorders: Depleted glutathione reserves increase vulnerability to NAPQI-mediated hepatic injury even at near-therapeutic doses.
Use with Caution
- Concurrent use of multiple acetaminophen-containing products: Review all medications for acetaminophen content to prevent inadvertent overdose.
- Severe renal impairment: Conjugated metabolites may accumulate. Extend dosing interval to q6–8h and reduce maximum daily dose.
- G6PD deficiency: Rare haemolytic anaemia reported; use with awareness in severe deficiency.
The FDA requires a boxed warning on all prescription acetaminophen-containing products regarding the risk of severe hepatotoxicity, including acute liver failure requiring transplantation or resulting in death. Hepatic injury is most commonly associated with doses exceeding the recommended maximum daily dose (often involving use of multiple acetaminophen-containing products) and with use in patients who consume three or more alcoholic beverages daily. The FDA has mandated that all prescription combination products contain no more than 325 mg of acetaminophen per dosage unit (2011 FDA Safety Communication).
Patient Counselling
Purpose of Therapy
Acetaminophen relieves mild to moderate pain (headaches, muscle aches, toothaches, menstrual cramps, arthritis) and reduces fever. It works differently from ibuprofen and aspirin and is generally gentler on the stomach, kidneys, and blood clotting.
How to Take
Take the lowest effective dose for the shortest duration needed. Follow the dosing instructions on the packaging carefully. Do not take more than the recommended dose. Do not take more than one acetaminophen-containing product at the same time. Extended-release tablets must be swallowed whole and not crushed or chewed.
Sources
- Acetaminophen injection prescribing information. Hikma Pharmaceuticals (formerly West-Ward). FDA LabelRegulatory source for IV acetaminophen dosing, pharmacokinetics, and safety data.
- FDA Drug Safety Communication: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit. January 2011. FDA.govKey regulatory action limiting prescription combination products to reduce hepatotoxicity risk.
- FDA Drug Safety Communication: Rare but serious skin reactions with acetaminophen. August 2013. FDA.govSafety communication documenting rare SJS/TEN/AGEP with acetaminophen.
- Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–1372. doi:10.1002/hep.20948Landmark US ALFSG study establishing acetaminophen as the leading cause of acute liver failure in the United States (46% of cases).
- Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002;40(1):3–20. doi:10.1081/CLT-120002882Comprehensive review by the creator of the Rumack-Matthew nomogram covering 35 years of acetaminophen toxicity data.
- Bunchorntavakul C, Reddy KR. Acetaminophen-related hepatotoxicity. Clin Liver Dis. 2013;17(4):587–607. doi:10.1016/j.cld.2013.07.005Thorough review of acetaminophen hepatotoxicity mechanisms, risk factors, and management strategies.
- Heard K, Dart R. Acetaminophen (paracetamol) poisoning in adults: treatment. UpToDate. Last updated 2025. UpToDateCurrent evidence-based guideline for NAC dosing, Rumack-Matthew nomogram interpretation, and overdose management.
- Mazaleuskaya LL, Sangkuhl K, Thorn CF, et al. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015;25(8):416–426. doi:10.1097/FPC.0000000000000150Definitive pharmacogenomic pathway analysis of acetaminophen metabolism including glucuronidation, sulfation, and NAPQI formation pathways.
- Andersson DA, Gentry C, Alenmyr L, et al. TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ(9)-tetrahydrocannabiorcol. Nat Commun. 2011;2:551. doi:10.1038/ncomms1559Key mechanistic study elucidating the role of TRPA1 and the endocannabinoid system in acetaminophen analgesia.
- Prescott LF. Paracetamol: past, present, and future. Am J Ther. 2000;7(2):143–147. doi:10.1097/00045391-200007020-00011Historical overview of paracetamol pharmacokinetics, therapeutic use, and safety profile by a pioneering researcher in the field.
- Acetaminophen. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. NCBI BookshelfContinuously updated clinical reference covering pharmacology, dosing, adverse effects, and monitoring.